FDA approves Pfizer's Inlyta

FDA approved Inlyta axitinib from Pfizer Inc. (NYSE:PFE) to treat advanced renal cell carcinoma after failure of one prior systemic therapy. In December, FDA's Oncologic Drugs Advisory Committee voted unanimously that data support a favorable risk-benefit profile for the inhibitor of VEGF receptors 1, 2 and 3 (see BioCentury Extra, Dec 7, 2011). ...